How to start your hybrid journey: LBA-LC/MS for large molecule quantitation

Combined Sciex & Algorithme1


Increased development of various large molecule therapeutics, such as proteins and peptides, has concurrently resulted in a greater demand for their quantitative bioanalysis. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) has established a foothold in reliably quantifying large molecules and is being increasingly used for this purpose. With the accessibility of specific immunoaffinity reagents and instrumentation, hybrid LBA-LC/MS assays are being routinely developed and utilized in bioanalytical laboratories in order to reach greater levels of sensitivity and selectivity. Through case studies, this presentation will offer strategies to overcome the challenges associated with the development of sensitive hybrid LBA-LC/MS assays for large-molecule quantification.

What will you learn?

  • Key challenges faced when developing LC-MS/MS bioanalysis of large molecules
  • Advantages of using hybrid LBA-LC/MS assays over traditional assays
  • How to simplify hybrid LBA-LC/MS using a semi-automated approach

Who may this interest?

  • CROs, pharmaceutical and biotechnology companies focused on LC-MS/MS quantitative bioanalysis of large molecules
  • Mass spectrometrists and bioanalytical chemists
  • Academics and students interested in LC-MS/MS bioanalysis


Gary Impey
Director, Pharma/CRO MS Business Unit

Gary received his PhD in Analytical Chemistry from York University in Toronto (Canada), in 1998 and quickly joined Apotex Pharmaceuticals where he worked in the analytical research & development department. His graduate work involved instrument design and development, which led him to join the team at SCIEX, demonstrating key features and benefits of the various mass spectrometry technologies to prospective customers. Currently, Gary is responsible for leading the quantitative and metabolism portion of the pharmaceutical & CRO mass spectrometry business at SCIEX. Part of Gary’s role involves the application of mass spectrometry technologies in all areas of the drug discovery and development process and helping to guide the product development cycle with strategies to bring better solutions to the marketplace.

Jean-Nicholas Mess speaker image BZ pageJean-Nicholas Mess
Manager and Scientific Advisor
Algorithme Pharma

Jean-Nicholas Mess holds a master’s degree in Biochemistry from the University of Montréal (QC, Canada), where he studied protein interactions in plant defense response to pathogen attack. In December 2004, Jean-Nicholas Mess joined Algorithme Pharma as a Method Development Scientist and has since participated in the publication of 12 peer-reviewed papers and more than 45 scientific posters on bioanalytical method development by LC-MS. Jean-Nicholas Mess currently holds the role of Manager and Scientific Advisor, New Molecular Entities, at Algorithme Pharma, where his focus is on developing the field of large molecule bioanalysis by LC-MS/MS and high resolution mass spectrometry in a regulated environment.

Click here to view the Q&A follow-up.

For a full list of other webinars available on Bioanalysis Zone please see here.